Pharma R&D investment report shows positive signs: Deloitte
According to the company’s 12th Annual Pharmaceutical Innovation Report, pharmaceutical R&D return on investment has climbed to its highest peak since 2014.
Stay updated with breaking news from Linical Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
According to the company’s 12th Annual Pharmaceutical Innovation Report, pharmaceutical R&D return on investment has climbed to its highest peak since 2014.
A leader from the company discusses challenges in control labs and shares how a new solution aims to clear some key obstacles to greater effectiveness.
With the amount of available data increasing and technology evolving, says a company leader, the job of data manager is more demanding than ever before.
The company plans to launch a Phase Ib/II study of its compound NVG-291 in collaboration with researchers at Northwestern University’s Shirley Ryan AbilityLab.
Joining with a noted research foundation, the group is aiming for earlier detection and treatment of the disease, which hits nearly 500K people annually.